难治性类风湿关节炎治疗策略的系统文献综述:当前证据更新
该系统文献综述更新了难治性类风湿关节炎(D2T RA)治疗策略的证据,检索至2025年7月,纳入131项研究。结果显示,在既往≥2种b/tsDMARDs失败的活动性RA患者中,除otilimab外所有b/tsDMARDs均优于安慰剂,JAKi疗效在既往bDMARD失败数增加时仍维持,但感染和恶性肿瘤风险增加。非药物干预证据有限,仅提示骨科手术可能为潜在选择。
要点
- 在既往≥2种b/tsDMARDs失败的活动性RA中,除otilimab外所有b/tsDMARDs均优于安慰剂。
- JAKi疗效在既往bDMARD失败数从1增至≥3时仍维持,但感染和恶性肿瘤风险增加。
- 非药物干预证据有限,仅提示骨科手术可能为D2T RA的潜在选择。
核心结论
- 该系统文献综述总结了DMARD在多种合并症中的疗效与安全性证据。
- 在既往≥2种bDMARD失败的活动性RA患者中,JAKi提供显著临床获益但需谨慎风险分层。
- 非药物干预的标准化报告和专门研究亟需开展。
研究设计与样本
- 系统文献综述,检索MEDLINE、Embase和Cochrane Library至2025年7月。
- 筛选8589条记录,纳入131项研究。
- 进行了Meta分析和Meta回归。
- PROSPERO注册号CRD42024593584。
主要发现
- 研究问题1:在肥胖、心血管疾病、恶性肿瘤病史和呼吸系统合并症等广泛合并症谱中综合了DMARD疗效与安全性证据。
- 研究问题2:除otilimab外所有b/tsDMARDs均显示优于安慰剂的疗效(多数高偏倚风险)。
- Meta回归显示JAKi疗效在既往bDMARD失败数从1增至≥3时仍维持。
- 安全性结果证实JAKi感染和恶性肿瘤发生增加。
- 研究问题3:有限证据提示骨科手术干预可能为D2T RA患者的非药物选择。
关键数值与推荐
- 研究问题1针对活动性疾病且治疗选择有限的患者。
- 研究问题2针对活动性疾病且既往≥2种b/tsDMARDs失败的患者。
- 研究问题3针对健康相关生活质量差且客观疾病活动度低的患者。
临床怎么用
- 在既往≥2种bDMARD失败的活动性RA患者中,可考虑JAKi但需根据心血管和恶性肿瘤风险谨慎分层。
- 对合并肥胖、心血管疾病、恶性肿瘤病史或呼吸系统合并症的患者,DMARD选择需参考综合证据。
- 非药物干预证据有限,骨科手术可作为D2T RA的潜在选择但需进一步研究。
局限性
- 研究问题2中多数b/tsDMARDs比较的证据存在高偏倚风险。
- 非药物干预的证据有限。
- 非药物干预缺乏标准化报告和专门研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This systematic literature review (SLR) aims to update the evidence regarding therapeutic strategies in difficult-to-treat rheumatoid arthritis (D2T RA), building on the previous SLR informing the European Alliance of Associations for Rheumatology (EULAR) points to consider for the management of D2T RA. METHODS: Three research questions addressed efficacy or safety of treatments in patients with RA with (1) active disease and limited treatment options; (2) active disease with ≥2 prior biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and (3) poor health-related quality of life and low objective disease activity (non-pharmacological interventions). MEDLINE, Embase and Cochrane Library were searched until July 2025. Meta-analysis and meta-regression were conducted. RESULTS: We screened 8589 records and included 131 studies. For research question (RQ)1, evidence on DMARD efficacy and safety was synthesised across a wide spectrum of comorbidities including obesity, cardiovascular disease, history of malignancy and respiratory comorbidities. For RQ2, all b/tsDMARDs except otilimab demonstrated better efficacy than placebo (mostly high risk of bias). Meta-regression showed efficacy was maintained for Janus kinase inhibitors (JAKi) despite increasing number of prior bDMARD failures (1 to ≥3). Safety results confirmed the increased occurrence of infection and malignancy with JAKi. For RQ3, limited evidence suggested orthopaedic surgical intervention as a potential non-pharmacological option in patients with D2T RA. CONCLUSIONS: This SLR summarised evidence supporting DMARD efficacy/safety across multiple comorbidities. In patients with active RA with ≥2 prior bDMARDs, JAKi offer substantial clinical benefits but require careful risk stratification given cardiovascular and malignancy risks. Furthermore, standardised reporting and dedicated studies on non-pharmacological interventions are urgently needed. PROSPERO REGISTRATION NUMBER: CRD42024593584.
引用
- Shams G, Dorgó AM, Ripepi C, et al. Therapeutic approaches for difficult-to-treat rheumatoid arthritis: a systematic literature review of current evidence. RMD Open. 2026. PMID: 42552072. doi:10.1136/rmdopen-2026-006860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。